

WHO WE ARE

- Created in 2012, as a result of the Spin off of P&G pharmaceuticals
- Focused in Women's health & Well being
- 100% private capital
- 25% of budget dedicated to R&D
- 2022 Turnover: 15 millions Euros

WHO WE ARE

Procare Health is a pharmaceutical company created in 2012, as a result of the spin off of P&G pharmaceuticals. Focused on Women's health & Wellbeing, Procare Health is a new pharmaceutical company based in Spain, constituted with 100% private equity.

Procare Health invests 25% of its budget in R&D, from basic research projects to ambitious clinical studies. Both research and development of Procare Health are conduced in Spain.

Basic and clinical investigation, innovation and formulation of products with natural ingredients are the key founding pillars to **Procare Health's** DNA, bringing the most appropriate solutions to nowadays women's aspirations and needs.



Procare Health gathers high experienced executives and team committed to create a dedicated and innovative pharmaceutical laboratory in Women health.

Procare Health will continue investigating, developing and manufacturing innovative solutions mostly formulated with Natural Active Principles

A JOURNEY INTO WOMEN'S HEALTH INNOVATION

- 2002-2007: WHI (the Women Health Initiative) published series of publication on CV and Breast cancer risks linked with hormones therapies.
- 2012: Procare was created to respond to the growing concerns of women in finding more natural alternatives to Hormones Replacement Therapies (HRT)

NATURAL BASED THERAPIES → NATURALLY WOMAN!

(Evidence Based Natural Healthcare)

• 2012-2017 : Procare launched its ambitious R&D program into

VAGINAL DISORDERS / INFECTIONS & FEMALE SEXUAL DYSFUNCTION

« Uncovered therapeutical needs »

• 2017 -2020: Procare launched its first products, doubling year by year its sales.



Procare 2 2012-2022
Naturally woman

COMPANY STRATEGIES

1

DRIVE INNOVATION:

Create, Investigate, develop and commercialize in house products line to improve women health

2

EXTEND PORTFOLIO & FOOTPRINT:

License-in New drugs in WH and launch new geographies (EU)

3

DEVELOP NEW STRATEGIC PARTNERSHIP:

- To improve our innovation and R&D
- To extend Procare Health's products footprint in the world

BUSINESS MODEL

Pull Model based on specialists calls among Gyn's and Rh's

- High seniority of the sales force team with best practice in Persuade
 P&G technical sales skills and best in class CRM tools
- Influence model: International Key Opinion Leaders and Scientific Societies endorsement (ex: IPVS, Eurogin, SEGO, SFPCV etc....)
- Distribution in Pharmacy via Wholesalers and Direct selling effort.

AREA OF EXPERTISE

1110			
	MM = N		

PAPILOCARE® - Human Papilomavirus

PALOMACARE® - Vaginal Atrophy

IDRACARE® - Vaginal Dryness

LIBICARE® - Female Sexual Dysfunction

LIBICARE MENO® / MENOCARE® - Menopause

IRONCARE® - Iron Food Supplement

OVOSICARE® - Fertility

JOINT HEALTH & PAIN MANAGEMENT

DOLOCARE® - Joint Pain (Spain)

PRONOLIS® - Hyaluronic Acid Injections

MICALDEOS - Calcium Food Supplement (Spain)

TIBICARE® - Female Sexual Dysfunction (Spain)

ARISOCARE® - Osteoporosis (Spain)

D-CARE[®] - Vitamine D (Spain)

PROCARE HEALTH Business Lines

























HEADQUARTER



WAREHOUSE & LOGISTICAL CENTER



- MANUFACTURING -PLANTS







INVESTIGATION CENTER I+D



PH's AFFILIATES





PROCARE HEALTH
PORTUGAL
Q1 2018



PROCARE HEALTH ITALIA Q4 2023

PROCARE WOMEN HEALTH Q1 2022

GLOBAL FOOTPRINT: WORLDWIDE DISTRIBUTORS





